$BIAFJul 27, 2026, 12:08 PMAI processed
bioAffinity publishes clinical framework to integrate CyPath® Lung for pulmonary nodule risk stratification
AI Summary
BioAffinity released a clinical white paper laying out specialty-specific pathways for incorporating its CyPath® Lung sputum-based test into primary care, pulmonology and oncology workflows to help evaluate pulmonary nodules and surveil cancer survivors. The company cites three years of commercial use and a published trial (92% sensitivity, 87% specificity, 99% NPV for nodules <20 mm) to argue CyPath Lung can complement imaging and blood tests and may reduce unnecessary invasive procedures, though it is marketed as an LDT and not a sole diagnostic.
Positives
- White paper provides concrete, specialty-specific clinical pathways for primary care, pulmonology and oncology integration
- Company cites three years of commercial experience and case studies showing consistent utility in stratifying malignancy risk
- Published trial reported 92% sensitivity, 87% specificity and 99% NPV for detecting cancer in high-risk patients with nodules <20 mm
Negatives
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended to be used as a sole diagnostic
- Wider adoption depends on physician uptake and could face competition from blood-based diagnostics
- Published performance was in a high-risk trial population with nodules <20 mm, which may limit generalizability